Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
Are there scenarios in which pericardiocentesis should be considered for large pericardial effusions without tamponade physiology?
Answer from: at Academic Institution
Yes
Sign in or Register to read more
28443
Related Questions
How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?
For SVG graft stenting, do you consider routinely embolic protection devices (EPD), and do you factor lesion location (prox vs distal) for decision making?
When measuring LV volumes on Echo using ultrasound enhancing agents, are you using different volume cut offs?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
Would you recommend normal saline for pre- and post-LHC hydration in patients with CKD stage III to IV with reduced LV systolic function, and if so, what is a reasonable amount of volume?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
What are your top takeaways from ACC 2025?
For a patient with prior bypass graft stenting and severe native vessel disease, would you recommend myocardial perfusion imaging or coronary CTA if there is concern about graft patency?
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?